Brentuximab vedotin, an antibody drug conjugate that binds to the protein CD30, showed promising benefits in a midstage trial involving 102 patients with Hodgkin lymphoma who received autologous stem cell transplants. About 10% of the study participants achieved long-term remission, raising the possibility that the drug may be curative for a subset of patients, said the University of Washington's Dr. Ajay Gopal.

Related Summaries